-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

BRIEF-Eisai Submits Supplemental Biologics License Application To U.S. FDA For Traditional Approval Of Leqembi To Treat Alzheimer's Disease

Reuters · 01/06/2023 23:52
BRIEF-Eisai Submits Supplemental Biologics License Application To U.S. FDA For Traditional Approval Of Leqembi To Treat Alzheimer's Disease

- Eisai Co Ltd 4523.T:

  • EISAI SUBMITS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION TO FDA FOR TRADITIONAL APPROVAL OF LEQEMBI™ (LECANEMAB-IRMB) FOR THE TREATMENT OF ALZHEIMER'S DISEASE

  • EISAI CO - CO PLANS TO FILE FOR MARKETING AUTHORIZATION APPLICATIONS OF LECANEMAB IN JAPAN & EU BY END OF EISAI’S FY2022, WHICH ENDS MARCH 31, 2023

Source text: https://bit.ly/3Qmqf2s

Further company coverage: 4523.T


((Reuters.Briefs@thomsonreuters.com;;))